BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 23820820)

  • 1. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
    Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
    Krauss S; Nalavade R; Weber S; Carter K; Evert BO
    Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
    Costa Mdo C; Luna-Cancalon K; Fischer S; Ashraf NS; Ouyang M; Dharia RM; Martin-Fishman L; Yang Y; Shakkottai VG; Davidson BL; Rodríguez-Lebrón E; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1898-908. PubMed ID: 23765441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
    Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.
    Huang F; Zhang L; Long Z; Chen Z; Hou X; Wang C; Peng H; Wang J; Li J; Duan R; Xia K; Chuang DM; Tang B; Jiang H
    FEBS Lett; 2014 Dec; 588(24):4791-8. PubMed ID: 25451224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript.
    Ramani B; Harris GM; Huang R; Seki T; Murphy GG; Costa Mdo C; Fischer S; Saunders TL; Xia G; McEachin RC; Paulson HL
    Hum Mol Genet; 2015 Mar; 24(5):1211-24. PubMed ID: 25320121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
    Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
    Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
    Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
    Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
    Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
    Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse ataxin-3 functional knock-out model.
    Switonski PM; Fiszer A; Kazmierska K; Kurpisz M; Krzyzosiak WJ; Figiel M
    Neuromolecular Med; 2011 Mar; 13(1):54-65. PubMed ID: 20945165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
    Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
    PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.